Skip to main content Back to Top


Epinephrine Auto-Injectors

Products Affected - Description

    • Epinephrine injection, Amneal, 0.15 mg/0.15 mL, auto-injector, 2 count, NDC 00115-1695-49
    • Epinephrine injection, Amneal, 0.3 mg/0.3 mL, auto-injector, 2 count, NDC 00115-1694-49

Reason for the Shortage

    • Amneal has discontinued Adrenaclick. Amneal acquired Impax in 2018.
    • Mylan refused to provide availability information.
    • Sandoz launched Symjepi in January 2019 and product is available.
    • Teva has FDA approval for generic epinephrine.

Available Products

    • Auvi-Q injection, Kaleo, 0.1 mg/0.1 mL, auto-injector, 2 count, NDC 60842-0021-01
    • Auvi-Q injection, Kaleo, 0.15 mg/0.15 mL, auto-injector, 2 count, NDC 60842-0022-01
    • Auvi-Q injection, Kaleo, 0.3 mg/0.3 mL, auto-injector, 2 count, NDC 60842-0023-01
    • Symjepi injection, Sandoz, 0.3 mg/0.3 mL, auto-injector, 2 count, NDC 00781-3442-20
    • Epinephrine injection, Teva, 0.3 mg/0.3 mL, auto-injector, 2 count, NDC 00093-5986-27

Estimated Resupply Dates

    • Amneal has epinephrine 0.15 mg/0.15 mL and 0.3 mg/0.3 mL auto-injectors on allocation.


    • FDA has extended the expiration dating for certain lots of EpiPen and some generic epinephrine auto-injectors.


Updated November 15, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 3, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins